Release Summary

Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Merck & Co., Inc.